Approval of second and third phase clinical trial of Russian vaccine Sputnik V in India

0

The Sputnik V vaccine has been created by the Russian Direct Investment Fund and the Gamalaya Scientific Research Institute of Epidemology. -File photo

  • On 16 September, the Russian Direct Investment Fund and Dr. Reddy agreed to a trial in India.
  • Sputnik V vaccine has been prepared by Gamalaya Research Institute of Epidemology.

Clearance of second and third phase clinical trials of Russian vaccine Sputnik V in India has been approved. The Drug Controller General of India (DCGI) has allowed the trial. The trial will be able to detect the effects of the vaccine on a large scale in the country. On 16 September, the Russian Direct Investment Fund (RDIF) and Dr. Reddy agreed to the trial and distribution of Sputnik V in India.

Dr. Reddy’s Laboratory Co-Chairman and MD G.V. “This is a significant development, which allows us to start clinical trials in India,” Prasad said in a statement. We are committed to bring a safe and effective vaccine to combat the epidemic. ”

Vaccine delivery may end by 2020

Earlier, RDIF said that 100 million doses of vaccine would be supplied to Dr. Reddy, a Hyderabad-based company in India. The Sputnik vaccine is based on the adenoviral vector platform, which is undergoing trials to prevent coronavirus epidemics. It was also said that the delivery could start in late 2020 after the successful testing and registration of the vaccine in India.

The Sputnik V vaccine has been created by the Russian Direct Investment Fund and the Gamalaya Scientific Research Institute of Epidemology. It was registered on 11 August.

Leave a Reply